Αchilles Anagnostopoulos

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations

Chrysoula Belessi, Carol Moreno, Myriam Boudjograh et al. · Blood · 2006 · 531 citations · Full text

Life Sciences, Immunology, Oncology +12

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

Fabio Ciceri, Chiara Bonini, Maria Teresa Lupo Stanghellini et al. · The Lancet Oncology · 2009 · 484 citations

Medicine, Hematology, Immunology +17

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Andreas Agathangelidis, Nikos Darzentas, Anastasia Hadzidimitriou et al. · Blood · 2012 · 387 citations · Full text

Life Sciences, Immunology, Oncology +17